Title
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)
Document Type
Presentation
Publication Date
12-6-2022
Keywords
oregon; portland; chiles
Clinical Institute
Cancer
Clinical Institute
Women & Children
Department
Oncology
Recommended Citation
Stanton, Sasha and See all authors in comments, "Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)" (2022). Articles, Abstracts, and Reports. 6995.
https://digitalcommons.providence.org/publications/6995
Comments
Stanton SE, MacDonald LD, Fiset S, Mellinger S, Moxon N, Hirsch H, Kelly TL, Young KH, Page DB. SABCS Annual Meeting; December 6-10; San Antonio, TX. 2022;40(16_suppl): TPS1119. doi: 10.1200/JCO.2022.40.16_suppl.TPS1119.